Accessibility Menu
 
Terns Pharmaceuticals logo

Terns Pharmaceuticals

(NASDAQ) TERN

This security has been delisted. This page is retained for historical reference.

TERN Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-20%

Return on Capital

-11%

Return on Assets

-9%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

$110.12M

EBITDA

$110.12M

Operating Cash Flow

$82.18M

Capital Expenditure

$0.00

Free Cash Flow

$82.18M

Cash & ST Invst.

$1.02B

Total Debt

$919.00K

Terns Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$108.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

N/A

Market Cap/Employee

N/A

N/A

Employees

59

N/A

Net Income

$23.57M

-8.1%

EBITDA

$34.37M

-33.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$1.02B

+185.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$445.00K

-51.6%

Short Term Debt

$474.00K

+10.7%

Return on Assets

-9.39%

N/A

Return on Invested Capital

-10.92%

N/A

Free Cash Flow

$19.08M

-30.8%

Operating Cash Flow

$19.08M

-30.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TRMLTourmaline Bio, Inc.
$47.98+0.00%
ORICORIC Pharmaceuticals, Inc.
$8.60-2.60%
PGENPrecigen, Inc.
$4.15+1.72%
IMTXImmatics N.V.
$10.79-5.27%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$16.84+0.06%
EOSEEos Energy Enterprises
$8.28+0.02%
TDICDreamland
$23.05+8.77%
APLSApellis Pharmaceuticals
$41.03-0.00%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.